Literature DB >> 18567874

Myasthenia gravis in the elderly: Is it different?

Johan A Aarli1.   

Abstract

We have defined myasthenia gravis (MG) in the elderly as onset after the age of 50 years. MG is diagnosed more often today than previously. The increase is mainly found in patients over the age of 50 years. Neurologists therefore see more old patients with MG now than before. Prevalence of the early-onset form of MG seems to be unchanged. Recent data indicate that MG may still be substantially underdiagnosed in very old people. Ptosis, diplopia, weakness of the facial muscles, and problems of articulation are important clinical signs in MG and are easier to detect in a youthful appearance. Since ageing causes a decrease in the total eyelid area with sagging of the lower eyelids, a ptosis may be more difficult to diagnose in the elderly. In addition, diplopia may not be detected because of reduced vision due to macular degeneration or cataract formation. Ocular symptoms of MG are therefore more easily missed in the elderly. Thymomatous MG is more common among older patients than it is in younger onset. The mean age at onset of MG for thymoma cases is 50-60 years. Approximately 10-15% of all MG patients have a thymoma, and around 40% of all thymoma cases are associated with MG. During normal aging, the thymus tissue becomes atrophic and replaced with fat. Recent data on MG thymus pathology suggest that lymphocyte accumulation indicating residual thymus may also be found in the elderly, and that there is little qualitative difference between the young and the old thymus from MG patients. The mean concentration of antibodies to acetylcholine receptor (AChR) is lower in MG in the elderly than in early-onset or thymoma-associated MG. Seronegative MG is less common among older patients. Approximately 30% of patients with late-onset, nonthymoma MG have antibodies to titin, while such antibodies are extremely scarce in early-onset MG. Titin antibodies in MG patients seem to be associated with a higher frequency of DR7 antigen and a decrease of DR3 antigen. The antibody response in MG may therefore be influenced by the genetic background.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18567874     DOI: 10.1196/annals.1405.040

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  35 in total

Review 1.  Diagnosis and management of autoimmune myasthenia gravis.

Authors:  Corrado Angelini
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

2.  Quality of life and life circumstances in German myasthenia gravis patients.

Authors:  Sabine Twork; Susanne Wiesmeth; Jörg Klewer; Dieter Pöhlau; Joachim Kugler
Journal:  Health Qual Life Outcomes       Date:  2010-11-11       Impact factor: 3.186

Review 3.  Treatment of myasthenia gravis: focus on pyridostigmine.

Authors:  Lorenzo Maggi; Renato Mantegazza
Journal:  Clin Drug Investig       Date:  2011-10-01       Impact factor: 2.859

4.  Myasthenia gravis mimicking stroke: a case series with sudden onset dysarthria.

Authors:  Lucio Tremolizzo; Federico Giopato; Maria Luisa Piatti; Andrea Rigamonti; Carlo Ferrarese; Ildebrando Appollonio
Journal:  Neurol Sci       Date:  2015-02-04       Impact factor: 3.307

Review 5.  Perioperative management in myasthenia gravis: republication of a systematic review and a proposal by the guideline committee of the Japanese Association for Chest Surgery 2014.

Authors:  Yoshihisa Kadota; Hirotoshi Horio; Takeshi Mori; Noriyoshi Sawabata; Taichiro Goto; Shin-ichi Yamashita; Takeshi Nagayasu; Akinori Iwasaki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-01-22

6.  Myasthenia gravis: a changing pattern of incidence.

Authors:  I Casetta; E Groppo; R De Gennaro; E Cesnik; L Piccolo; S Volpato; E Granieri
Journal:  J Neurol       Date:  2010-07-11       Impact factor: 4.849

7.  Candida esophagitis as the cause of swallowing disturbances in an 85-year-old patient with myasthenia gravis.

Authors:  S Ebert; K-P Schweiger; R Nau
Journal:  Z Gerontol Geriatr       Date:  2011-08       Impact factor: 1.281

8.  Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis.

Authors:  Isabell Cordts; Nicolas Bodart; Kathi Hartmann; Katerina Karagiorgou; John S Tzartos; Lin Mei; Jens Reimann; Philip Van Damme; Michael H Rivner; Alain Vigneron; Joachim Weis; Jörg B Schulz; Socrates J Tzartos; Kristl G Claeys
Journal:  J Neurol       Date:  2017-05-17       Impact factor: 4.849

Review 9.  Vasculitis: determinants of disease patterns.

Authors:  Gary S Hoffman; Leonard H Calabrese
Journal:  Nat Rev Rheumatol       Date:  2014-06-17       Impact factor: 20.543

10.  A genome-wide association study of myasthenia gravis.

Authors:  Alan E Renton; Hannah A Pliner; Carlo Provenzano; Amelia Evoli; Roberta Ricciardi; Michael A Nalls; Giuseppe Marangi; Yevgeniya Abramzon; Sampath Arepalli; Sean Chong; Dena G Hernandez; Janel O Johnson; Emanuela Bartoccioni; Flavia Scuderi; Michelangelo Maestri; J Raphael Gibbs; Edoardo Errichiello; Adriano Chiò; Gabriella Restagno; Mario Sabatelli; Mark Macek; Sonja W Scholz; Andrea Corse; Vinay Chaudhry; Michael Benatar; Richard J Barohn; April McVey; Mamatha Pasnoor; Mazen M Dimachkie; Julie Rowin; John Kissel; Miriam Freimer; Henry J Kaminski; Donald B Sanders; Bernadette Lipscomb; Janice M Massey; Manisha Chopra; James F Howard; Wilma J Koopman; Michael W Nicolle; Robert M Pascuzzi; Alan Pestronk; Charlie Wulf; Julaine Florence; Derrick Blackmore; Aimee Soloway; Zaeem Siddiqi; Srikanth Muppidi; Gil Wolfe; David Richman; Michelle M Mezei; Theresa Jiwa; Joel Oger; Daniel B Drachman; Bryan J Traynor
Journal:  JAMA Neurol       Date:  2015-04       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.